GTN
London
About GTN
Bringing a single new drug to the market costs $2.9bn, often delivering an intervention that barely differs from those already in the market. Projections into the future are not promising, with an expected 50% drop in R&D output every nine years. At GTN they are searching the astronomically large space of drug-like molecules with their unique patented technology, Generative Tensorial Networks. Their software combines and builds upon techniques from machine learning and quantum physics to simulate, filter and search for molecules, halving development costs and discovering molecules entirely hidden from view.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $2.8M
- Funding stage: Seed
- Last round: Seed (Nov 2018)
- Website: gtn.ai
- Phone: [email protected]
Industries & Categories
Biotechnology, Chemical, Machine Learning, Quantum Computing
Social Profiles
Canonical: https://fsome.com/organization/gtn-12326 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.